EUROBIO-SCIENTIFIC (ALERS.PA) Stock Fundamental Analysis

EPA:ALERS • FR0013240934

23 EUR
-0.45 (-1.92%)
Last: Feb 19, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ALERS. ALERS was compared to 78 industry peers in the Biotechnology industry. ALERS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ALERS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ALERS had positive earnings in the past year.
  • In the past year ALERS had a positive cash flow from operations.
  • ALERS had positive earnings in each of the past 5 years.
  • ALERS had a positive operating cash flow in each of the past 5 years.
ALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

1.2 Ratios

  • ALERS has a Return On Assets of 0.91%. This is in the better half of the industry: ALERS outperforms 75.64% of its industry peers.
  • Looking at the Return On Equity, with a value of 1.30%, ALERS is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
  • ALERS has a better Return On Invested Capital (4.00%) than 78.21% of its industry peers.
  • ALERS had an Average Return On Invested Capital over the past 3 years of 5.13%. This is significantly below the industry average of 11.39%.
Industry RankSector Rank
ROA 0.91%
ROE 1.3%
ROIC 4%
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
ALERS.PA Yearly ROA, ROE, ROICALERS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

1.3 Margins

  • ALERS has a Profit Margin of 1.46%. This is in the better half of the industry: ALERS outperforms 76.92% of its industry peers.
  • ALERS's Profit Margin has declined in the last couple of years.
  • The Operating Margin of ALERS (7.62%) is better than 78.21% of its industry peers.
  • ALERS's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 46.95%, ALERS perfoms like the industry average, outperforming 47.44% of the companies in the same industry.
  • ALERS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.62%
PM (TTM) 1.46%
GM 46.95%
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
ALERS.PA Yearly Profit, Operating, Gross MarginsALERS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALERS is destroying value.
  • Compared to 1 year ago, ALERS has about the same amount of shares outstanding.
  • Compared to 5 years ago, ALERS has less shares outstanding
  • Compared to 1 year ago, ALERS has an improved debt to assets ratio.
ALERS.PA Yearly Shares OutstandingALERS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALERS.PA Yearly Total Debt VS Total AssetsALERS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 3.67 indicates that ALERS is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.67, ALERS is doing good in the industry, outperforming 71.79% of the companies in the same industry.
  • ALERS has a debt to FCF ratio of 1.48. This is a very positive value and a sign of high solvency as it would only need 1.48 years to pay back of all of its debts.
  • ALERS's Debt to FCF ratio of 1.48 is amongst the best of the industry. ALERS outperforms 87.18% of its industry peers.
  • ALERS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
  • ALERS has a Debt to Equity ratio of 0.07. This is in the better half of the industry: ALERS outperforms 69.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 1.48
Altman-Z 3.67
ROIC/WACC0.56
WACC7.11%
ALERS.PA Yearly LT Debt VS Equity VS FCFALERS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.79 indicates that ALERS should not have too much problems paying its short term obligations.
  • ALERS's Current ratio of 1.79 is in line compared to the rest of the industry. ALERS outperforms 44.87% of its industry peers.
  • A Quick Ratio of 1.25 indicates that ALERS should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.25, ALERS is doing worse than 61.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.25
ALERS.PA Yearly Current Assets VS Current LiabilitesALERS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • ALERS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -63.27%.
  • The Earnings Per Share has been growing slightly by 6.82% on average over the past years.
  • ALERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.47%.
  • Measured over the past years, ALERS shows a very strong growth in Revenue. The Revenue has been growing by 21.21% on average per year.
EPS 1Y (TTM)-63.27%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%

3.2 Future

  • Based on estimates for the next years, ALERS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.32% on average per year.
  • The Revenue is expected to grow by 12.90% on average over the next years. This is quite good.
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALERS.PA Yearly Revenue VS EstimatesALERS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALERS.PA Yearly EPS VS EstimatesALERS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • ALERS is valuated quite expensively with a Price/Earnings ratio of 100.00.
  • ALERS's Price/Earnings ratio is a bit cheaper when compared to the industry. ALERS is cheaper than 78.21% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.09, ALERS is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 19.76, the valuation of ALERS can be described as rather expensive.
  • 87.18% of the companies in the same industry are more expensive than ALERS, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of ALERS to the average of the S&P500 Index (27.98), we can say ALERS is valued slightly cheaper.
Industry RankSector Rank
PE 100
Fwd PE 19.76
ALERS.PA Price Earnings VS Forward Price EarningsALERS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALERS is valued cheaply inside the industry as 93.59% of the companies are valued more expensively.
  • 88.46% of the companies in the same industry are more expensive than ALERS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.83
EV/EBITDA 7.49
ALERS.PA Per share dataALERS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • ALERS has a very decent profitability rating, which may justify a higher PE ratio.
  • ALERS's earnings are expected to grow with 13.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)14.67
EPS Next 2Y13.32%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALERS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EUROBIO-SCIENTIFIC

EPA:ALERS (2/19/2026, 7:00:00 PM)

23

-0.45 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-27
Earnings (Next)N/A
Inst Owners2.81%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap235.75M
Revenue(TTM)162.09M
Net Income(TTM)2.36M
Analysts84.44
Price Target30.6 (33.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 100
Fwd PE 19.76
P/S 1.45
P/FCF 20.83
P/OCF 16.43
P/B 1.3
P/tB 7.28
EV/EBITDA 7.49
EPS(TTM)0.23
EY1%
EPS(NY)1.16
Fwd EY5.06%
FCF(TTM)1.1
FCFY4.8%
OCF(TTM)1.4
OCFY6.09%
SpS15.81
BVpS17.71
TBVpS3.16
PEG (NY)N/A
PEG (5Y)14.67
Graham Number9.57
Profitability
Industry RankSector Rank
ROA 0.91%
ROE 1.3%
ROCE 6.02%
ROIC 4%
ROICexc 4.6%
ROICexgc 27.98%
OM 7.62%
PM (TTM) 1.46%
GM 46.95%
FCFM 6.98%
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
ROICexc(3y)7.07%
ROICexc(5y)35.47%
ROICexgc(3y)44.03%
ROICexgc(5y)78.19%
ROCE(3y)7.73%
ROCE(5y)25.78%
ROICexgc growth 3Y-35.35%
ROICexgc growth 5Y49.79%
ROICexc growth 3Y-58%
ROICexc growth 5Y39.27%
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 1.48
Debt/EBITDA 0.41
Cap/Depr 16.48%
Cap/Sales 1.87%
Interest Coverage 250
Cash Conversion 46.68%
Profit Quality 479.21%
Current Ratio 1.79
Quick Ratio 1.25
Altman-Z 3.67
F-Score6
WACC7.11%
ROIC/WACC0.56
Cap/Depr(3y)26.09%
Cap/Depr(5y)27.29%
Cap/Sales(3y)2.36%
Cap/Sales(5y)1.86%
Profit Quality(3y)322.49%
Profit Quality(5y)228.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-63.27%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.15%
EBIT growth 3Y-42.09%
EBIT growth 5Y88.7%
EBIT Next Year18.88%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.42%
FCF growth 3Y-40.57%
FCF growth 5Y31.67%
OCF growth 1Y-49.85%
OCF growth 3Y-36.72%
OCF growth 5Y27.33%

EUROBIO-SCIENTIFIC / ALERS.PA FAQ

What is the ChartMill fundamental rating of EUROBIO-SCIENTIFIC (ALERS.PA) stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA.


What is the valuation status for ALERS stock?

ChartMill assigns a valuation rating of 5 / 10 to EUROBIO-SCIENTIFIC (ALERS.PA). This can be considered as Fairly Valued.


How profitable is EUROBIO-SCIENTIFIC (ALERS.PA) stock?

EUROBIO-SCIENTIFIC (ALERS.PA) has a profitability rating of 6 / 10.


What is the earnings growth outlook for EUROBIO-SCIENTIFIC?

The Earnings per Share (EPS) of EUROBIO-SCIENTIFIC (ALERS.PA) is expected to decline by -11.36% in the next year.